TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Positive and negative predictive value of 18FACBC PET/MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC(0-last)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement from baseline mitral regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychometric validity of the PR25 module
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CAD (Chronic Allograft Dysfunction) Degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Atazanavir persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival Rate at 4-month (16 Weeks)
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral hemiparesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: IVC Collapsibility Index Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uptake of labelled neutrophils in the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall incidence of device related Major Adverse Cardiac and Neurological Events (MACNE)
Endpoint domain: Adverse events/effects
Primary endpoint: BSA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of esophagitis grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life as assessed using the EORTC QLQ-C15-PAL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to L-Dopa start
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial wrinkles reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Absolute Bioavailability (%F) for TAK-831
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration of TAK-831
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity of TAK-831
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic urinary incontinence measured by ICIQ-SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of s-CD95-L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Sum Score (TSS) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High and Low Contrast Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading Acuity and Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of skin irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin barrier integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Abdominal Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool Consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nature and frequency of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory parameters (haematology, biochemistry and urinalysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical examinations and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated Wrist Evaluation (PRWE) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of Hematopoietic Reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive dysfunction prevalence and incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: State-Trait Anxiety Inventory (STAI-I)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State-Trait Anxiety Inventory (STAI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tomographic changes in bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Occurrence of violence
Endpoint domain: Adverse events/effects
Primary endpoint: Prognostic value of post thyroidectomy 99mTCpertechnetate thyroid scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbation of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of MRIs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Somatic mutation burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients using Computerized Depression Guideline instruments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pelvic Varicose Veins Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Probable PTSD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitreous Haze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Chamber Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable iron isotope appearance in the plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Day of Surgery Pain Scores at 6 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid and Analgesic Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Experience Common Opioid and Analgesic Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Range of Motion (degrees)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to pulp sensibility testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Clinically Relevant Decrease in ESSDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score (self)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in HDV-RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time to receive chronic pain treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Absence of Newly Formed Intrauterine Adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cancer affected prepubertal boys undergoing testicular cryopreservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction in depressive symptoms (>= 50% HAMD score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wakening After Sleep Onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Grade 3-4 Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Glasgow Scale Outcome Extended (GOSE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical and radiological resolution of the PFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of radiological resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time in range (TIR) 70 - 180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: OX40L expression in endothelial cells and skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of albendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue among Medical Doctors
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Concentration of ITC in blood after consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for Any Intermittent Catheterization Postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fistula Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in mean pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: number of women with episiotomy and vaginal tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) of Tocilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Tocilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Plasma Concentration (Cmin) of Tocilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who are completely blocked fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of the 8-week telehealth program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of the 8-week telehealth program
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Signal of efficacy of the telehealth program - overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6-month Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Risk for developing lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tear break up time (TBUT) at postoperative 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI) at postoperative 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meibomian gland dysfunction (MGD) stage at postoperative 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIF-1alpha expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD-complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dialysis Clearance (CLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Extraction Coefficient of MK-7655
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fibroblast Growth Factor (FGF) 23 Mean Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month change in CD4 T-cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 12-month proportion of patients whose HIV viral load (VL) level is detectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of HCV tests processed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of adverse pregnancy outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of new onset postoperative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: Change of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Checklist Individual Strength, CIS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change of Visual Display Terminals visual syndrome, VDTs fatigue scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative occurrence of confirmed VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Transprosthetic aortic gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in New York Heart Association (NYHA) class
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of visits to healthcare services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Main health provider visited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mechanical Properties of Patient's Breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Diurnal IOP Change From Baseline at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Arthritis Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of HCV GT3-infected Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Study Drug Discontinued Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Intentions to Reduce Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Importance of Reducing Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Intentions to Reduce Marijuana Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Importance of Reducing Marijuana Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Illinois agility test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplant related mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of grade III-IV acute (or overlap) graft versus host disease (GvHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Ixazomib related grade III-IV toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge and perception regarding JSSK and RBSK
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Assessment of Cancer Therapy scale (FACT-G)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients with any TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Heat sensation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of pelvic organ prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Resolution Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean area under the curve (AUC) of enalaprilat plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined RTSS and RMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family accommodation improvement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Sleep log
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Beck Suicide Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self Management
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of subjects with COPD on inappropriate inhalers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in St George's Respiratory Questionnaire (SGRQ) Score in 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the forced expiratory volume in the first second (FEV1) in 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in shortness of breath in 3 months measured using the San Diego Shortness of breath Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: estimated blood loss after caesarean delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive and Negative Syndrome Scale (PANSS)- Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrated Numeric Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue Analgesic Medication Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for future onset of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate from positive to negative swaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Satisfaction With Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resting interpalpebral fissure size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mRNA quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End tidal CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non invasive arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non invasive stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inspiratory and expiratory times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the amount of dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the amount of gingival bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of periodontal pockets 4 mm or deeper
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in values for the quality of life instrument QoL-AD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in values for the oral health related quality of life instrument OHIP-14
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm birth less than 34+0 gestational weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Preeclampsia before 34+0 gestational weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Severe fetal growth restrictions earlier than 34+0 gestational weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Nightime Mean Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of knee pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12 points clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood level of pimecrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrapartum Caesarean delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient compliance to Ketosteril
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Grade 3 or Higher Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of estimated fetal weight by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Transition time from initiation to full oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Berg Balance Scale (BBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of Syndecan-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes